Details

Autor(en) / Beteiligte

• Neuzil, Kathleen M.
• Jackson, Lisa A.
• Nelson, Jennifer
• Klimov, Alexander
• Cox, Nancy
• Bridges, Carolyn B.
• Dunn, John
• DeStefano, Frank
• Shay, David

Titel

Immunogenicity and Reactogenicity of 1 versus 2 Doses of Trivalent Inactivated Influenza Vaccine in Vaccine-Naive 5–8-Year-Old Children

Ist Teil von

• The Journal of infectious diseases, 2006-10, Vol.194 (8), p.1032-1039

Ort / Verlag

United States: The University of Chicago Press

Erscheinungsjahr

2006

Link zum Volltext

Quelle

Oxford Journals 2020 Medicine

Beschreibungen/Notizen

• BackgroundTwo doses of trivalent inactivated influenza vaccine (TIV) are recommended for children <9 years old receiving vaccine for the first time, but compliance is suboptimal. This study assessed the need for a second dose of TIV in this age group MethodsIn this prospective, open-label study, 232 influenza vaccine–naive 5–8-year-olds enrolled in a health maintenance organization received 2 doses of TIV in fall 2004. Serum for antibody titer measurement was obtained at 3 time points (n=222). Parents completed diaries for 5 days ResultsBoth doses of vaccine were well tolerated. The strongest predictor of a protective antibody response (⩾1:40) after 1 dose of TIV was baseline seropositive status. In multivariate analysis adjusting for age, sex, and baseline serostatus, the proportion of children with protective antibody responses was significantly higher after 2 doses than after 1 dose of TIV for each antigen (P<.001, for A/H1N1; P=.01, for A/H3N2; P<.001, for B). Age and sex were not independently predictive of a protective antibody response. Over one-third of children had antibody responses <1:40 for the type B vaccine component, even after 2 doses ConclusionsThe present study supports the need for 2 doses of TIV in 5–8-year-olds receiving TIV for the first time. Efforts to increase compliance with the 2-dose recommendation are warranted